BD has announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been CE marked to the IVD Directive (98/79/EC).BD plans to produce 8 million SARS-CoV-2 antigen tests per month by October and 12 million tests per month by March 2021.

Regeneron has announced the first data from a descriptive analysis of a Phase 1/2/3 trial of the investigational antibody cocktail known as "REGN-COV2". Results show that it reduced viral load and alleviated symptoms in non-hospitalized patients with COVID-19.

PerkinElmer, Inc., introduced cloud-based software to provide continuous quality control for food and food ingredient manufacturing processes. The new solution is designed to enable food producers to increase efficiency and improve margins by reducing waste, optimizing the use of expensive raw materials and increasing product consistency.

A new ELISA test has been developed to aid in the analysis of identifying neutralizing antibodies towards SARS-CoV-2.

Daicel Arbor Biosciences, a division of Chiral Technologies, Inc., announces the launch of their new line of myBaits Custom Methyl-Seq target capture kits. This pairs an innovative methyl-seq probe design algorithm with a highly optimized target capture protocol to efficiently enrich target genes and markers of interest from converted methyl-seq NGS libraries.

The first volunteers have been safely dosed in COVAXX's Phase 1, open-label, dose-escalation study of the UB-612 vaccine candidate for COVID-19 in Taiwan.

VIPS™ + MatriClone™ combination ensures high efficiency seeding of hiPSCs with high viability.

Amarna Therapeutics has announced today that it has entered into a collaboration with scientists from the Progreso y Salud Foundation (FPS) at Cabimer in Seville, to jointly examine the efficacy of Amarna’s SVec™ gene delivery vector for the development of effective immunotherapies for diabetes mellitus type 1 (DM1) and multiple sclerosis (MS).

Sartorius has joined the group of shareholders of the German Research Center for Artificial Intelligence (DFKI). The two companies are currently conducting research on deep learning algorithms and methods for image recognition of cells and organoids, analysis and modeling of biological systems, and for simulation and optimization of biopharmaceutical production processes.

A case report published today in The Lancet Respiratory Medicine outlines the first compassionate use of recombinant soluble human ACE2 (APN01) to treat a female 45-year-old patient who was diagnosed with severe COVID-19.